Eli Lilly & Co. stock (US5324571083): CVS coverage expansion and Q1 momentum keep focus on U.S. growth

Eli Lilly & Co. shares continue to attract attention in the United States after the New York Stock Exchange-listed stock recently combined blockbuster first-quarter 2026 results with a key commercial win at CVS Caremark for its obesity portfolio. According to NYSE data cited by MarketBeat, Eli Lilly traded around USD 1,080 on 06/01/2026 after a 2.3% pullback, with intraday lows near USD 1,071.60 and trading volume of roughly 2.65 million shares. On the U.S. side, this places the Indianapolis-based S&P 500 constituent firmly in the spotlight as investors weigh strong fundamentals against a rich valuation backdrop.

The latest fundamental driver came from Q1 2026 earnings, where Eli Lilly reported revenue of USD 19.8 billion, an increase of 55.5% year on year, and earnings per share of USD 8.55 versus analyst expectations of USD 6.97, according to MarketBeat and other market commentary on the quarter. The company also raised its full-year 2026 revenue guidance to a range of USD 82 billion to USD 85 billion in its Q1 update, which was highlighted in coverage by TheStreet as a significant step-up versus prior expectations. In a U.S. home-country context, such figures underscore how much of the company’s growth narrative is currently driven by demand for its metabolic and diabetes treatments, particularly obesity therapies.

On the commercial front, TheStreet recently reported that CVS Caremark has agreed to provide coverage for Eli Lilly’s obesity therapies Zepbound and the newly authorized once-daily obesity drug Foundayo starting in the summer of 2026. With Zepbound and Foundayo now covered across all three major U.S. pharmacy benefit managers, Eli Lilly’s obesity portfolio gains broader access to the U.S. insured population, with the CVS formulary alone estimated to reach 25 million to 30 million Americans, according to figures cited from The Boston Globe in TheStreet’s analysis. This move was described as helping Eli Lilly reach parity with Novo Nordisk in terms of formulary inclusion for weight-loss therapies, marking an important U.S.-centric competitive milestone.

Market commentary has pointed out that Eli Lilly shares rose about 5% around the time of the CVS announcement, illustrating how closely the New York market tracks incremental access gains for high-profile drug franchises. While the share price has since eased from recent highs, MarketBeat notes that the stock maintains a supportive balance sheet profile, with a current ratio of roughly 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of about 1.26, according to its latest trading snapshot as of 06/01/2026. In Germany, the U.S. stock is available via off-exchange trading venues such as Tradegate under the ticker LLY, giving euro-based investors access in parallel to the primary NYSE listing.

Beyond the equity, Eli Lilly has also been active in capital markets housekeeping. A recent Form 25 filing with the U.S. Securities and Exchange Commission, reported by StockTitan, showed that Eli Lilly requested the removal of its 1.625% notes due 2026 from NYSE listing and registration. The filing relates to a specific debt security rather than the common stock; there is no indication in the SEC documentation that the ordinary shares are being delisted, and regular trading activity on the NYSE has continued. This kind of selective delisting is typically administrative and often follows redemptions or maturities of particular bond issues.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

Eli Lilly & Co.: core business model

Eli Lilly & Co. develops and markets patented prescription medicines, with current growth anchored in its obesity and diabetes franchises alongside oncology and immunology therapies that generate recurring revenue from large chronic-patient populations.

Latest quarterly results for Eli Lilly & Co. at a glance

The company’s Q1 2026 numbers marked a step-change in scale, with revenue of USD 19.8 billion up 55.5% compared with the prior-year quarter, as highlighted in post-earnings analysis that drew on Eli Lilly’s latest financial disclosures and market commentary. The same coverage noted that earnings per share reached USD 8.55 for the quarter, substantially ahead of the USD 6.97 consensus cited by MarketBeat, indicating that both top line and profitability surprised positively versus Wall Street expectations. Commentators linked the outperformance primarily to rapid uptake of obesity drugs and robust demand in diabetes care, set against continued contributions from oncology and immunology brands.

In its Q1 2026 guidance update, Eli Lilly raised its full-year 2026 revenue outlook to a corridor of USD 82 billion to USD 85 billion, according to figures discussed by TheStreet when reviewing the quarter. While the prior revenue outlook range was not highlighted in the same secondary sources, the new range was presented as an increase relative to earlier internal planning and as a signal of management confidence that elevated demand levels in obesity care can be sustained over the remainder of the year. For U.S.-based investors following earnings quality, the combination of faster revenue growth, guidance uplift and leverage to high-margin therapies has reinforced the perception that the current cycle is earnings-driven rather than purely sentiment-led.

Conclusion

Eli Lilly & Co.’s latest Q1 2026 earnings performance, including a 55.5% year-on-year revenue increase to USD 19.8 billion and EPS of USD 8.55 versus a USD 6.97 consensus, has reinforced the United States-based company’s position as one of the fastest-growing large pharma names on the NYSE. The lift in full-year 2026 revenue guidance to USD 82 billion to USD 85 billion and the broadened CVS Caremark coverage for obesity drugs such as Zepbound and Foundayo underscore how much of the investment narrative now hinges on access and uptake in the U.S. market. Against this backdrop, investors monitoring the stock from both the U.S. and European trading venues are likely to continue focusing on execution in obesity and diabetes care, pricing and reimbursement dynamics, and the sustainability of earnings growth implied by current expectations.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.